The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (272 million pounds) over five years over Washington's insistence on sensitive biological samples.
This rejection was revealed after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
An official representative later clarified that the United States was requesting health data for research and commercial gain while was not willing to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued talks to find a deal suitable to all parties so the country's critical HIV treatment initiative can continue.
Broader Implications
This rejection follows a similar situation in Kenya, where a court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research without any certainty that the end products would be available to our people should a future disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting structures already established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but recommended that negotiations must proceed since much of the nation's Aids initiatives relied on external financing.
"If technical issues exist, including those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
The halted deal underscores the continuing tensions between receiving crucial international aid and protecting a country's data in an ever more data-driven world.